Tracon Pharmaceuticals Inc (NASDAQ:TCON) had an increase of its short interest by 73.68%. It was announced in April by FINRA the 430,200 short interest on TCON. The up change of 73.68% from 247,700 shares was reported. With Average volume 401,200, TCON’s previous position will take 1 days to recover. Float short on Tracon Pharmaceuticals Inc is 2.97%.

TCON hit $0.6623 during the last trading session after $0.6377 change.TRACON Pharmaceuticals, Inc. has 3.63 million shares volume, 597.17% up from normal. TCON is downtrending and has moved 47.35% since April 14, 2018. TCON underperformed by 51.72% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is valued at $19.80 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Last it reported negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news brought out briefly go to: Globenewswire.com, Seekingalpha.com, Seekingalpha.com, Globenewswire.com or Benzinga.com. The titles are as follows: “TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference – GlobeNewswire” brought out on May 31, 2018, “TRACON Pharmaceuticals and I-Mab Biopharma collaborates for multiple immuno-oncology programs – Seeking Alpha” on November 29, 2018, “APC, PE, IMRN and MDXG among notable midday movers – Seeking Alpha” with a publish date: April 12, 2019, “TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting – GlobeNewswire” and the last “The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings (Feb. 17-23) – Benzinga” with publication date: February 15, 2019.